RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.
暂无分享,去创建一个
A. Dombkowski | J. Taub | L. Matherly | J. Boerner | S. Buck | Y. Ge | C. Xie | K. Lafiura | Holly Edwards | Katherine M. Lafiura | Alan A. Dombkowski
[1] A. Baruchel,et al. Activating mutations in human acute megakaryoblastic leukemia. , 2008, Blood.
[2] J. Fontana,et al. Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group , 2008, Oncogene.
[3] C. Pui,et al. Acute lymphoblastic leukaemia , 2008, The Lancet.
[4] A. Dombkowski,et al. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy , 2008, Leukemia.
[5] J. Hitzler. Acute megakaryoblastic leukemia in Down syndrome , 2007, Pediatric blood & cancer.
[6] Danielle Boller,et al. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. , 2007, Critical reviews in oncology/hematology.
[7] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[8] C. Bloomfield,et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A M Martelli,et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia , 2006, Leukemia.
[10] M. Loh,et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. , 2006, Blood.
[11] F. Ferrara,et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. , 2006, Blood.
[12] Hongyue Dai,et al. Rosetta error model for gene expression analysis , 2006, Bioinform..
[13] Y. Hayashi,et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. , 2006, Blood.
[14] Aravind Subramanian,et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[15] A. Dombkowski,et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. , 2006, Blood.
[16] E. Estey,et al. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. , 2006, Blood.
[17] E. Solary,et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .
[18] D. Reinhardt,et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity , 2005, Leukemia.
[19] J. Harbott,et al. Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment , 2005, Leukemia.
[20] Y. Ravindranath,et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. , 2005, Journal of the National Cancer Institute.
[21] Todd A Alonzo,et al. Mortality in overweight and underweight children with acute myeloid leukemia. , 2005, JAMA.
[22] J. Downing,et al. Gene expression profiling of pediatric acute myelogenous leukemia. , 2004, Blood.
[23] L. Peterson,et al. The 8;21 translocation in leukemogenesis , 2004, Oncogene.
[24] S. Richards,et al. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome , 2003, Leukemia.
[25] R. Arceci,et al. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia , 2003, Current oncology reports.
[26] T. Alonzo,et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Paredes-Aguilera,et al. Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children , 2003, American journal of hematology.
[28] J. Taub,et al. Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. , 2003, Blood.
[29] M. Vignetti,et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials , 2002, Leukemia.
[30] Yoshiaki Ito,et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. , 2002, Blood.
[31] F. Behm,et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. , 2001, Blood.
[32] T. L. Witt,et al. Repression of Human Reduced Folate Carrier Gene Expression by Wild Type p53* , 2001, The Journal of Biological Chemistry.
[33] D. Neuberg,et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. , 2000, Blood.
[34] G. Gustafsson,et al. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? , 2000, Leukemia.
[35] R. Hanada,et al. The Treatment Outcome of Acute Megakaryocytic Leukemia in Down Syndrome , 2000 .
[36] S. Hiebert,et al. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. , 2000, Gene.
[37] M. Caligiuri,et al. Molecular and Clinical Advances in Core Binding Factor Primary Acute Myeloid Leukemia: A Paradigm for Translational Research in Malignant Hematology , 2000, Cancer investigation.
[38] John M. Maris,et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.
[39] J. Buckley,et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. , 1998, Blood.
[40] J. Zhang,et al. The AML1/ETO fusion protein activates transcription of BCL-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[41] F. Alt,et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. , 1996, Cell.
[42] F. Alt,et al. The CBFβ Subunit Is Essential for CBFα2 (AML1) Function In Vivo , 1996, Cell.
[43] R. Bronson,et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[44] J. Krischer,et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood , 1996 .
[45] M. Marín‐Padilla,et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[46] J. Downing,et al. AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis , 1996, Cell.
[47] M. Gossen,et al. Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.
[48] A. Zipursky,et al. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. , 1994, Leukemia research.
[49] J. Krischer,et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. , 1992, Blood.
[50] C. Pui,et al. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia , 2007, Cancer.
[51] G. Peters,et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. , 2002, Blood.
[52] M. Eguchi,et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome , 2000, Leukemia.
[54] J. Krischer,et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. , 1996, The New England journal of medicine.
[55] J. Krischer,et al. Acute Myeloid Leukemia ( AML ) in Down ' s Syndrome Is Highly Responsive to Chemotherapy : Experience on Pediatric Oncology Group AML Study , 2022 .